BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

728 related articles for article (PubMed ID: 19826418)

  • 21. Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study.
    Kim JH; Lee SC; Oh SY; Song SY; Lee N; Nam EM; Lee S; Hwang IG; Lee HR; Lee KT; Bae SB; Kim HJ; Jang JS; Lim DH; Lee HW; Kang SY; Kang JH
    Cancer Commun (Lond); 2018 Jun; 38(1):32. PubMed ID: 29866170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
    Goel A; Grossbard ML; Malamud S; Homel P; Dietrich M; Rodriguez T; Mirzoyev T; Kozuch P
    Anticancer Drugs; 2007 Mar; 18(3):263-71. PubMed ID: 17264757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumour activity of three second-line treatment combinations in patients with metastatic colorectal cancer after optimal 5-FU regimen failure: a randomised, multicentre phase II study.
    Rougier P; Lepille D; Bennouna J; Marre A; Ducreux M; Mignot L; Hua A; Méry-Mignard D
    Ann Oncol; 2002 Oct; 13(10):1558-67. PubMed ID: 12377643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study.
    Taïeb J; Lecomte T; Aparicio T; Asnacios A; Mansourbakht T; Artru P; Fallik D; Spano JP; Landi B; Lledo G; Desrame J
    Ann Oncol; 2007 Mar; 18(3):498-503. PubMed ID: 17158774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
    Li J; Saif MW
    JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
    Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
    Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
    Blazer M; Wu C; Goldberg RM; Phillips G; Schmidt C; Muscarella P; Wuthrick E; Williams TM; Reardon J; Ellison EC; Bloomston M; Bekaii-Saab T
    Ann Surg Oncol; 2015 Apr; 22(4):1153-9. PubMed ID: 25358667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis.
    Kang BW; Kim TW; Lee JL; Ryu MH; Chang HM; Yu CS; Kim JC; Kim JH; Kang YK; Lee JS
    Med Oncol; 2009; 26(1):32-7. PubMed ID: 18498064
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
    Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW
    Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
    Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
    Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated metastatic exocrine pancreatic cancer: Phase I results.
    Carrato A; Vieitez JM; Benavides M; Rodriguez-Garrote M; Castillo A; Ogalla GD; Bermejo LG; Ruiz de Mena I; Guillén-Ponce C; Aranda E;
    Eur J Cancer; 2020 Nov; 139():51-58. PubMed ID: 32977220
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxaliplatin plus irinotecan and leucovorin-modulated 5-fluorouracil triplet regimen every other week: a dose-finding study in patients with advanced gastrointestinal malignancies.
    Comella P; Casaretti R; De Rosa V; Avallone A; Izzo F; Fiore F; Lapenta L; Comella G
    Ann Oncol; 2002 Dec; 13(12):1874-81. PubMed ID: 12453855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
    Oh SY; Kim HJ; Kim TH; Lee GW; Kim HG; Jeong CY; Kwon HC; Kang JH
    Invest New Drugs; 2010 Jun; 28(3):343-9. PubMed ID: 19444385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
    Gourgou-Bourgade S; Bascoul-Mollevi C; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Boige V; Bérille J; Conroy T
    J Clin Oncol; 2013 Jan; 31(1):23-9. PubMed ID: 23213101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.
    Bupathi M; Ahn DH; Wu C; Ciombor KK; Stephens JA; Reardon J; Goldstein DA; Bekaii-Saab T
    Med Oncol; 2016 Apr; 33(4):37. PubMed ID: 26995224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
    Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
    Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.
    Ch'ang HJ; Wang CC; Cheng AL; Hsu C; Lu YS; Chang MC; Lin JT; Wang HP; Shiah HS; Liu TW; Chang JY; Whang-Peng J; Chen LT
    J Gastroenterol Hepatol; 2006 May; 21(5):874-9. PubMed ID: 16704539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
    El-Hadaad HA; Wahba HA
    J Gastrointest Cancer; 2013 Sep; 44(3):313-7. PubMed ID: 23606201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
    Kim SH; Shin SJ; Kim SY; Lee SH; Park YS; Park SH; Lee KH; Kim TW; Hong YS; Ahn JB
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):91-7. PubMed ID: 21607556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.